Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
2022 · Leukemia · 62 citations
https://doi.org/10.1038/s41375-022-01637-7
A
Aaron T. Gerds
Cleveland Clinic(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
722
Papers
6.7K
Citations
40
h-index
133
i10-index
Aaron T. Gerds is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Myeloproliferative Neoplasms: Diagnosis and Treatment & Acute Myeloid Leukemia Research & Chronic Myeloid Leukemia Treatments. The author has an h-index of 40, co-authored 614 publications.
ORCID: 0000-0002-3422-1309Papers by this author
worksRusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera
2024 · New England Journal of Medicine · 41 citations
https://doi.org/10.1056/nejmoa2308809
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study
2019 · Biology of Blood and Marrow Transplantation · 34 citations
https://doi.org/10.1016/j.bbmt.2019.10.017
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
2024 · Blood Advances · 28 citations
https://doi.org/10.1182/bloodadvances.2023011514
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
2025 · Nature Medicine · 23 citations
https://doi.org/10.1038/s41591-025-03572-3
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
2019 · Annals of Hematology · 22 citations
https://doi.org/10.1007/s00277-019-03799-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat